By Turna Ray

Following US District Court Judge Robert Sweet's decision earlier this month to not rule from the bench as to whether Myriad Genetics' BRCA gene patents are legally and constitutionally valid, it is anyone's guess as to when the judge may issue a determination on the case. Nevertheless, some legal experts predict that the judge may be waiting to decide the American Civil Liberties Union's anti-gene patenting case in order to see how the Supreme Court handles the method claims in Bilski v. Kappos.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

PLOS Biology has asked researchers how they envision the future of genetics and genomics.

Representative Lamar Smith brings back a provision to require the National Science Foundation to certify that each study it funds is "in the national interest."

The US Food and Drug Administration has approved four molecularly targeted drugs this month, suggesting that personalized medicine has "turned a corner."

In Science this week: caution urged in use of gene drives, and more.